MRK

Merck & Co
NYSE

Real-time Quotes | Nasdaq Last Sale

83.15
+0.52
+0.63%
After Hours: 83.60 +0.45 +0.54% 18:18 09/24 EDT
OPEN
82.10
PREV CLOSE
82.63
HIGH
83.48
LOW
81.85
VOLUME
7.48M
TURNOVER
--
52 WEEK HIGH
92.64
52 WEEK LOW
65.25
MARKET CAP
210.31B
P/E (TTM)
20.15
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Investors Are Scrambling To Get Ahead Of The Oncology Drug Market Boom; 1 Company Could Revolutionize The Industry
The opportunity for companies within this sector is massive. We are now talking about a global industry that is currently worth over $ 141 billion with the potential in the next 7 years to be worth over $ 394 billion.
Benzinga · 7h ago
Dow's nearly 50-point jump highlighted by gains in shares of Goldman Sachs, Apple Inc.
The Dow Jones Industrial Average is climbing Thursday afternoon with shares of Goldman Sachs and Apple Inc. seeing positive momentum for the blue-chip...
marketwatch.com · 9h ago
Mixed Data From ESMO Sets Up The Next Fight For Exelixis
The CheckMate-9ER of Cabometyx and Opdivo was successful, but not definitively superior to the established combo of Pfizer's Inlyta and Merck's Keytruda.The Cabo-Opdivo combo appeared to work better in sicker patients, and the better tolerability (notably lower discontinuations) could be another argument in its favor.I don't necessarily see Cabo-Opdivo becoming #1 in front-line RCC in the U.S., but I believe the combo can help drive U.S. RCC sales to $2.4 billion.Exelixis has some early-stage clinical assets, but the success of Cabo in RCC is the real key if the stock is to reach my $29 fair value estimate.
Seekingalpha · 12h ago
All six COVID-19 vaccines in industrial manufacturing - HHS Secretary Azar
Bloomberg reports that, according to Health and Human Services ((HHS)) Secretary Alex Azar, all six frontrunning COVID-19 vaccines are being produced at industrial scale.The companies have all previously announced production
Seekingalpha · 16h ago
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23)
Benzinga · 17h ago
NEXPLANON® Contraceptive Arm Implant Now Available for Use in Canada
* NEXPLANON® is the first single-rod arm implant to be approved by Health Canada for the prevention of pregnancy.1 * The implant provides Canadians with a new birth control option that can be removed at any point during the three-year period by a healthcare professional.
CNW Group · 18h ago
Fintech Focus For September 24, 2020
Benzinga · 1d ago
Johnson & Johnson stock outperforms competitors on strong trading day
Shares of Johnson & Johnson inched 0.16% higher to $144.44 Wednesday, on what proved to be an all-around rough trading session for the stock market, with...
marketwatch.com · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRK. Analyze the recent business situations of Merck & Co through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRK stock price target is 95.94 with a high estimate of 107.00 and a low estimate of 84.00.
EPS
Institutional Holdings
Institutions: 2.43K
Institutional Holdings: 2.01B
% Owned: 78.95%
Shares Outstanding: 2.53B
TypeInstitutionsShares
Increased
931
99.18M
New
115
13.96M
Decreased
921
87.61M
Sold Out
84
4.60M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.83%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Chief Executive Officer/President/Director
Kenneth Frazier
Chief Financial Officer/Executive Vice President
Robert Davis
Chief Human Resource Officer/Executive Vice President
Steven Mizell
Executive Vice President/Chief Marketing Officer
Michael Nally
Executive Vice President/General Counsel/Secretary
Jennifer Zachary
Executive Vice President
Sanat Chattopadhyay
Executive Vice President
Frank Clyburn
Executive Vice President
Franklin Clyburn
Executive Vice President
Richard DeLuca
Executive Vice President
Julie Gerberding
Executive Vice President
Roger Perlmutter
Senior Vice President - Finance/Controller
Rita Karachun
Senior Vice President/Chief Compliance Officer
Michael Fleming
Lead Director/Independent Director
Leslie Brun
Independent Director
Thomas Cech
Independent Director
Mary Coe
Independent Director
Pamela Craig
Independent Director
Thomas Glocer
Independent Director
Paul Rothman
Independent Director
Patricia Russo
Independent Director
Christine Seidman
Independent Director
Inge Thulin
Independent Director
Kathy Warden
Independent Director
Peter Wendell
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
07/28/2020
Dividend USD 0.61
09/14/2020
05/26/2020
Dividend USD 0.61
06/12/2020
01/28/2020
Dividend USD 0.61
03/13/2020
11/19/2019
Dividend USD 0.61
12/13/2019
07/23/2019
Dividend USD 0.55
09/13/2019
05/28/2019
Dividend USD 0.55
06/14/2019
01/29/2019
Dividend USD 0.55
03/14/2019
10/25/2018
Dividend USD 0.55
12/14/2018
07/24/2018
Dividend USD 0.48
09/14/2018
05/22/2018
Dividend USD 0.48
06/14/2018
01/23/2018
Dividend USD 0.48
03/14/2018
11/28/2017
Dividend USD 0.48
12/14/2017
07/26/2017
Dividend USD 0.47
09/14/2017
05/23/2017
Dividend USD 0.47
06/13/2017
03/01/2017
Dividend USD 0.47
03/13/2017
11/22/2016
Dividend USD 0.47
12/13/2016
07/26/2016
Dividend USD 0.46
09/13/2016
05/24/2016
Dividend USD 0.46
06/13/2016
02/23/2016
Dividend USD 0.46
03/11/2016
11/24/2015
Dividend USD 0.46
12/11/2015
07/22/2015
Dividend USD 0.45
09/11/2015
05/26/2015
Dividend USD 0.45
06/11/2015
02/24/2015
Dividend USD 0.45
03/12/2015
11/25/2014
Dividend USD 0.45
12/11/2014
07/23/2014
Dividend USD 0.44
09/11/2014
05/27/2014
Dividend USD 0.44
06/12/2014
02/25/2014
Dividend USD 0.44
03/13/2014
11/26/2013
Dividend USD 0.44
12/12/2013
07/25/2013
Dividend USD 0.43
09/12/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MRK
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Merck & Co., Inc. stock information, including NYSE:MRK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRK stock methods without spending real money on the virtual paper trading platform.